Log in to search using one of your social media accounts:

 

Therapy of Early Chronic Phase Chronic Myeloid Leukemia (CML-CP) with Lower Dose Dasatinib

Dasatinib is a potent tyrosine kinase inhibitor (TKI) of BCR-ABL. Approved dose in the chronic phase is 100mg daily. This is however associated with notable side effects mainly myelosuppression and pleural effusion, leading to dose reductions/interruptions.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research

Related Links:

Tyrosine kinase inhibitors (TKIs) can safely be discontinued in chronic myeloid leukemia (CML) patients with sustained deep molecular response (DMR). ABCG2, OCT1 and ABCB1 (MDR1) gene products are known to play a crucial role in acquired pharmacogenetic TKI resistance. Their influence on treatment-free remission (TFR) has not yet been investigated.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
In this study, we assessed the efficacy and toxicity of imatinib therapy in patients with chronic myeloid leukemia in chronic phase (CML-CP) in our hospital.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
CONCLUSION: After a median follow-up of 8 years, imatinib was found to induce long survival with manageable side effect in adult Saudi patients with CML-CP. PMID: 29397347 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Clin Lymphoma Myeloma Leuk Source Type: research
Publication date: Available online 29 November 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Stuart L. Goldberg, Michael Savona, Michael J. Mauro BCR-ABL1 tyrosine kinase inhibitors have dramatically improved outcomes for patients with chronic myeloid leukemia, and current studies are investigating whether some patients may be able to suspend therapy yet maintain response in a state known as “treatment-free remission” (TFR). Results from ongoing studies suggest that ≈ 40% to 60% of patients in sustained (generally ≥ 2 years) deep molecular response (defined as a 4-log or deeper reducti...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
We describe the clinicopathologic features of 17 patients who had a hematologic malignancy of various types, were treated, and subsequently developed a lymphoproliferative disorder (LPD). There were 10 men and 7 women with a median age of 59 years (range, 36 to 83 y). The primary hematologic neoplasms included: 5 chronic lymphocytic leukemia/small lymphocytic lymphoma, 3 plasma cell myeloma, 2 acute monoblastic leukemia, and 1 case each of mixed-phenotype acute leukemia, chronic myeloid leukemia, splenic marginal zone lymphoma, follicular lymphoma, mantle cell lymphoma, T-cell prolymphocytic leukemia, and peripheral...
Source: The American Journal of Surgical Pathology - Category: Pathology Tags: Original Articles Source Type: research
BCR-ABL1 tyrosine kinase inhibitors have dramatically improved outcomes for patients with chronic myeloid leukemia, and current studies are investigating whether some patients may be able to suspend therapy yet maintain response in a state known as “treatment-free remission” (TFR). Results from ongoing studies suggest that ≈ 40% to 60% of patients in sustained (generally ≥ 2 years) deep molecular response (defined as a 4-log or deeper reduction in BCR-ABL1 transcripts, depending on the study) who attempt TFR may successfully remain off treatment.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Leukemia in Remission;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Myeloid Leukemia With FLT3/ITD Mutation;   Acute Myeloid Leukemia With Gene Mutations;   Aplastic Anemia;   B-Cell Non-Hodgkin Lymphoma;   CD40 Ligand Deficiency;   Chronic Granulomatous Disease;   Chronic Leukemia in Remission;   Chronic Lymphocytic&n...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Michael J. Mauro, Jorge E. Cortes, Andreas Hochhaus, Neil P. Shah, Ehab Atallah, Mena Abaskharoun, Oumar Sy, Giuseppe Saglio
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Kiran Naqvi, Jorge Cortes, Jeffrey Skinner, Elias Jabbour, Naveen Pemmaraju, Gautam Borthakur, Zeev Estrov, Prithviraj Bose, Philip Thompson, Hagop Kantarjian
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Hee-Je Kim, Hea-Lyun Yoo, Won-Sik Lee, Hyeong-Joon Kim, Jee Hyun Kong, Yunsuk Choi, Young Rok Do, Jae-Yong Kwak, Sukjoong Oh, Sung Hyun Kim, Jeong-A. Kim, Dae Young Zang, Yeung-Chul Mun, Young-Woong Won, Sung-Eun Lee, Dong-Wook Kim
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Leukemia | Lymphoma | Myeloma